Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 13Lung Neoplasms 5Head and Neck Neoplasms 3Colorectal Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Rectal Neoplasms 2Gliosarcoma 2Glioblastoma 2Colonic Neoplasms 2Untreated Childhood Anaplastic Astrocytoma 1Thoracic Neoplasms 1Subjects With Resectable Local or Locally Advanced, Non-Metastatic (T2-T4, N0-N3, M0; Stages II and III) and Histologically-Confirmed Intestinal GC 1Skin Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Prostatic Neoplasms 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Non-Metastatic Prostate Cancer 1Neoplasms, Glandular and Epithelial 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasms 1Nasopharyngeal Carcinoma 1Lung Diseases 1Fallopian Tube Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Central Nervous System Neoplasms 1

Interventions

tremelimumab 1poly(I).poly(c12,U) 1olaparib 1lentiviral minigene vaccine of COVID-19 coronavirus 1genexol-PM 1abagovomab 1Topotecan 1Paclitaxel 1Oxaliplatin 1MOC31PE immunotoxin 1LY-2157299 1Introns 1Interferon alpha-2 1Hyperthermic Intraperitoneal Chemotherapy 1Gefitinib 1Drug Therapy 1Doxorubicin 1Cytoreduction Surgical Procedures 1Cisplatin 1Celecoxib 1Capecitabine 1Bevacizumab 1AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase 1Acids 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Peritoneal Neoplasms × Gefitinib × Clear all
NCT00317772 2022-02-07

Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer

M.D. Anderson Cancer Center

Phase 1/2 Completed
19 enrolled 12 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡